ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2017³â 9¿ù 22ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F] |
GO1-GO5 (08:20~09:10) |
ÁÂÀå : ±è¿µÅÂ(¿¬¼¼ÀÇ´ë) |
GO108:20~08:30 |
Á¶ÀçÇö ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Optimal tumour size for stage IB1-IIA2 cervical cancer : MRI vs Pathology vs colposcopy |
GO208:30~08:40 |
¿À¼öÇö ÀüºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Increase in sub-tumor temperature and blood flow in cervical carcinoma by heating with modulated electro-hyperthermia(mEHT) |
GO308:40~08:50 |
¾î°æÁø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Two-step sentinel lymph node mapping strategy in endometrial cancer using fluorescent
imaging: a pilot observational study |
GO408:50~09:00 |
ÀÌ°Ç¿ì ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Effectiveness of Sentinel Lymph Node Mapping: Comparison with MRI, PET/CT in early
cervical and endometrial cancer surgery |
GO509:00~09:10 |
±è¹Ì¼± ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Adjuvant therapy for improving survival outcomes in women with uterine-confined endometrial cancer of endometrioid grade 3, serous papillary and clear cell histology: A multicenter study |
GO6-GO10 (09:10~10:00) |
ÁÂÀå : ±èÀç¿ø(¼¿ïÀÇ´ë) |
GO609:10~09:20 |
ÀÌ¿ëÀç ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer |
GO709:20~09:30 |
¹Ú¼öÁø ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Asian perspective on the quality of debulking surgery for advanced-stage ovarian cancer:
Results of an international survey |
GO809:30~09:40 |
³ëÁØÈ£ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Comparison of RNA-seq and microarray of gene expression signatures
as a predictor of survival in six selected cancers |
GO909:40~09:50 |
¾î°æÁø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Mutated exon level in BRCA1 may influence the clinical course of BRCA1-mutated epithelial ovarian cancer |
GO1009:50~10:00 |
¼³¾Ö¶õ ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Genomic landscape of ovarian clear cell carcinoma via next generation sequencing
cancer |
GO11-GO15 (10:30~11:20) |
ÁÂÀå : ±è¿ë¹ü(¼¿ïÀÇ´ë) |
GO1110:30~10:40 |
±Çº´¼ö ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
The role of microRNA-424/503-WEE1 axis in ovarian cancer stem like cells |
GO1210:40~10:50 |
±è¹Ì¼± ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Identification of histology-specific expression of HOX genes and tailored strategy for
overcoming the resistance to platinum in epithelial ovarian cancer |
GO1310:50~11:00 |
Ȳµ¿¿ø ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø »êºÎÀΰú |
Ketone body suppresses human ovarian cancer
via modulation of mammalian target of rapamycin: A pilot study
|
GO1411:00~11:10 |
¿À¼öÇö ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Maspin expression related with hypoxia affects prognosis of clear cell carcinoma of the ovary |
GO1511:10~11:20 |
À±°¡¿µ ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Long Interspersed Element-1 Open Reading Frame 1 Protein Expression Profiles in Ovarian
Cancers |
GO16-GO20 (11:20~12:10) |
ÁÂÀå : ±è±âÇü(ºÎ»êÀÇ´ë) |
GO1611:20~11:30 |
±èÁöȯ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer:
consecutive imaging, frailty assessment, and diagnostic laparoscopy. |
GO1711:30~11:40 |
Á¤ÈñÁ¤ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Low value of staging procedure in detecting omental and peritoneal occult metastasis in mucinous borderline ovarian tumors |
GO1811:40~11:50 |
¾öÁ¤¹Î ÇѾç´ëÇб³º´¿ø »êºÎÀΰú |
Optimal debulking surgery including systemic pelvic and para-aortic lymphadenectomy, is it possible during laparoscopic interval debulking surgery after neoadjuvant chemotherapy in ovarian cancer? |
GO1911:50~12:00 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Anti-cancer effect of axitinib in ovarian cancer |
GO2012:00~12:10 |
¿Á±¸½½ ¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú |
Role of radiation therapy in recurrent ovarian cancer |
GO21-GO24 (12:10~12:50) |
ÁÂÀå : ¼º¼®ÁÖ(Â÷ÀÇ°úÇдë) |
GO2112:10~12:20 |
±èÀ±Áö ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Pretreatment neutrophil-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer |
GO2212:20~12:30 |
ÀÌÀÎÇÏ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
External validation of dynamic change of CA-125 as a predictive and prognostic in patients
with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy |
GO2312:30~12:40 |
Á¶Çö³ç ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Prognostic value of preoperative lymphocyte-monocyte ratio in elderly patients with advanced epithelial ovarian cancer |
GO2412:40~12:50 |
ÇÑ¿µÁö ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
The survival analysis of advanced stage epithelia ovarian / fallopian tube / primary peritoneum carcinoma according to performance of high complexity upper abdominal surgery |
GO25-GO28 (14:00~14:40) |
ÁÂÀå : ÀÌÁ¾ÇÐ(°æ»óÀÇ´ë) |
GO2514:00~14:10 |
ÀÌ¾Æ¶ó °¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú |
Risk factors of diagnostic discrepancy between colposcopically directed biopsies and loop electrosurgical excision procedure conization of the uterine cervix |
GO2614:10~14:20 |
º¯Á¤¹Ì ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú |
The clinical significance of a pattern-based classification system in management of endocervical adenocarcinoma |
GO2714:20~14:30 |
È«¾Æ¸§ ÀüºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) as biomarkers in women with cervical cancer or cervical dysplasia |
GO2814:30~14:40 |
±è¹Î°æ Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer |
GO29-GO32 (14:40~15:20) |
ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë) |
GO2914:40~14:50 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Machine Learning-guided Staging in Patients with Epithelial Ovarian Cancer |
GO3014:50~15:00 |
½ÅÁ¤¾ð Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Robot (Xi) assisted transperitoneal infrarenal lymphadenectomy by Vessel sealer robot instrument |
GO3115:00~15:10 |
ÀÌÀººñ °è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú |
Robotic single site versus robotic
multiport radical hysterectomy c pelvic node dissection in early cervical cancer
: a case control study
|
GO3215:10~15:20 |
¾öÁ¤¹Î ÇѾç´ëÇб³º´¿ø »êºÎÀΰú |
Impact of morcellation on recurrence of patients with cellular leiomyoma after laparoscopic
myomectomy |
GO33-GO37 (15:20~16:10) |
ÁÂÀå : ±è¿µÅ¹(¿ï»êÀÇ´ë) |
GO3315:20~15:30 |
±è¼±¾Æ
|
Clinical outcome of high-grade cervical intraepithelial neoplasia during pregnancy: A 10-year experience |
GO3415:30~15:40 |
±èÇüÁÖ ¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú |
Young age is associated with aggressive feature, radioresistance, and relative lymphopenia
in cervical cancer |
GO3515:40~15:50 |
±èÇý°æ ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Evaluation of the pelvic autonomic nerve function and quality of life related with the pelvic
organs after type C1 hysterectomy in patients with early-stage cervical cancer |
GO3615:50~16:00 |
Àå°æÁø ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Clinical characteristics of long-term ovarian cancer survivors: A study of prognostic inflection points
for long-term survivorship in advanced epithelial ovarian cancer
|
GO3716:00~16:10 |
±è¹Ì¼± ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
A nomogram for predicting the risk of lower extremity lymphedema in patients undergoing
lymphadenectomy for gynecologic cancers |
GO38-GO42 (16:10~17:00) |
ÁÂÀå : ±è¼º¿±(Á¦ÁÖÀÇ´ë) |
GO3816:10~16:20 |
±èÁöÇý ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Preclinical trial of targeted agents using NGS and PDX models in Gyn Cancer |
GO3916:20~16:30 |
±èÁöÇý ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
The study about anti-cancer mechanism of tetraarsenic oxide in cervical cancer using cell line and PDX model |
GO4016:30~16:40 |
Ãֽ¿µ °í·ÁÀÇ´ë ¾È»êº´¿ø »êºÎÀΰú |
³¼Ò¾Ï, Àڱ󻸷¾Ï ȯÀÚÀÇ ±âÀúÁúȯ°ú HE4 °ªÀÇ ¿¬°ü¼º
|
GO4116:40~16:50 |
±èÇÏ¿¬ ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
The utility of MLH1 methylation test for Lynch syndrome screening in endometrial cancer patients |
GO4216:50~17:00 |
½ÅÁ¤¾ð °æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Comparison of robotic-assisted versus laparoscopy for transperitoneal infrarenal paraaortic
lymphadenectomy in patients with endometrial cancer |